Literature DB >> 11157802

Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13).

I Panagopoulos1, T Fioretos, M Isaksson, U Samuelsson, R Billström, B Strömbeck, F Mitelman, B Johansson.   

Abstract

The CBP gene at 16p13 fuses to MOZ and MLL as a result of the t(8;16)(p11;p13) in acute (myelo)monocytic leukemias (AML M4/M5) and the t(11;16)(q23;p13) in treatment-related AML, respectively. We show here that a novel t(10;16)(q22;p13) in a childhood AML M5a leads to a MORF-CBP chimera. RT-PCR using MORF forward and CBP reverse primers amplified a MORF-CBP fusion in which nucleotide 3103 of MORF was fused in-frame with nucleotide 284 of CBP. Nested RT-PCR with CBP forward and MORF reverse primers generated a CBP-MORF transcript in which nucleotide 283 of CBP was fused in-frame with nucleotide 3104 of MORF. Genomic analyses revealed that the breaks were close to Alu elements in intron 16 of MORF and intron 2 of CBP and that duplications had occurred near the breakpoints. A database search using MORF cDNA enabled us to construct an exon-intron map of the MORF gene. The MORF-CBP protein retains the zinc fingers, two nuclear localization signals, the histone acetyltransferase (HAT) domain, a portion of the acidic domain of MORF and the CBP protein downstream of codon 29. Thus, the part of CBP encoding the RARA-binding domain, the CREB-binding domain, the three Cys/His-rich regions, the bromodomain, the HAT domain and the Glu-rich domains is present. In the reciprocal CBP-MORF, part of the acidic domain and the C-terminal Ser- and Met-rich regions of MORF are likely to be driven by the CBP promoter. Since both fusion transcripts were present, their exact role in the leukemogenic process remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157802     DOI: 10.1093/hmg/10.4.395

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  48 in total

1.  Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein.

Authors:  I Kitabayashi; Y Aikawa; L A Nguyen; A Yokoyama; M Ohki
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

2.  Whole-exome-sequencing identifies mutations in histone acetyltransferase gene KAT6B in individuals with the Say-Barber-Biesecker variant of Ohdo syndrome.

Authors:  Jill Clayton-Smith; James O'Sullivan; Sarah Daly; Sanjeev Bhaskar; Ruth Day; Beverley Anderson; Anne K Voss; Tim Thomas; Leslie G Biesecker; Philip Smith; Alan Fryer; Kate E Chandler; Bronwyn Kerr; May Tassabehji; Sally-Ann Lynch; Malgorzata Krajewska-Walasek; Shane McKee; Janine Smith; Elizabeth Sweeney; Sahar Mansour; Shehla Mohammed; Dian Donnai; Graeme Black
Journal:  Am J Hum Genet       Date:  2011-11-11       Impact factor: 11.025

3.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

Review 4.  Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation.

Authors:  Gerald V Denis
Journal:  Discov Med       Date:  2010-12       Impact factor: 2.970

5.  Preparation of polyclonal antibody specific for BRD7 and detection of its expression pattern in the human fetus.

Authors:  Huaying Liu; Xiaoling Li; Zhaoxia Niu; Liming Zhang; Ming Zhou; He Huang; Jiajin He; Wenling Zhang; Lan Xiao; Yunlian Tang; Li Wang; Guiyuan Li
Journal:  J Histochem Cytochem       Date:  2007-12-10       Impact factor: 2.479

Review 6.  Crosstalk between epigenetic readers regulates the MOZ/MORF HAT complexes.

Authors:  Brianna J Klein; Marie-Eve Lalonde; Jacques Côté; Xiang-Jiao Yang; Tatiana G Kutateladze
Journal:  Epigenetics       Date:  2013-10-29       Impact factor: 4.528

Review 7.  Leukaemogenesis: more than mutant genes.

Authors:  Jianjun Chen; Olatoyosi Odenike; Janet D Rowley
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

Review 8.  Protein lysine acetylation by p300/CBP.

Authors:  Beverley M Dancy; Philip A Cole
Journal:  Chem Rev       Date:  2015-01-16       Impact factor: 60.622

Review 9.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

10.  Tandem PHD fingers of MORF/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin.

Authors:  Muzaffar Ali; Kezhi Yan; Marie-Eve Lalonde; Cindy Degerny; Scott B Rothbart; Brian D Strahl; Jacques Côté; Xiang-Jiao Yang; Tatiana G Kutateladze
Journal:  J Mol Biol       Date:  2012-10-12       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.